<DOC>
	<DOCNO>NCT00006155</DOCNO>
	<brief_summary>SU5416 , novel antiangiogenesis agent , show potent selective inhibitor tyrosine kinase activity FlK-1 ( downstream effector VEGF ) vitro inhibit growth endothelial cell . Since VEGF mRNA level vessel count tumor tissue show inversely related prognosis ovarian cancer , SU5416 may prove useful agent disease . Platinum agent currently provide effective treatment ovarian cancer . However , ovarian cancer often become refractory platinum therapy , leave patient poor prognosis . This phase I study design : ) determine dose level carboplatin use combination establish dose SU5416 treatment patient platinum-refractory ovarian cancer , b ) ass side effect profile SU5416 carboplatin combination therapy , c ) characterize alteration SU5416 pharmacokinetic pharmacodynamic parameter give combination carboplatin , ) characterize carboplatin pharmacokinetic pharmacodynamic parameter give combination SU5416 , e ) exploratory study assess effect SU5416 platinum-DNA adduct level , f ) exploratory study assess alteration ERCC1 mRNA level carboplatin administer SU5416 , g ) obtain preliminary evidence ability SU5416 reverse platinum resistance patient platinum-refractory ovarian carcinoma .</brief_summary>
	<brief_title>SU5416 Carboplatin Treat Ovarian Cancer</brief_title>
	<detailed_description>SU5416 , novel antiangiogenesis agent , show potent selective inhibitor tyrosine kinase activity FlK-1 ( downstream effector VEGF ) vitro inhibit growth endothelial cell . Since VEGF mRNA level vessel count tumor tissue show inversely related prognosis ovarian cancer , SU5416 may prove useful agent disease . Platinum agent currently provide effective treatment ovarian cancer . However , ovarian cancer often become refractory platinum therapy , leave patient poor prognosis . This phase I study design : ) determine dose level carboplatin use combination establish dose SU5416 treatment patient platinum-refractory ovarian cancer , b ) ass side effect profile SU5416 carboplatin combination therapy , c ) characterize alteration SU5416 pharmacokinetic pharmacodynamic parameter give combination carboplatin , ) characterize carboplatin pharmacokinetic pharmacodynamic parameter give combination SU5416 , e ) exploratory study assess effect SU5416 platinum-DNA adduct level , f ) exploratory study assess alteration ERCC1 mRNA level carboplatin administer SU5416 , g ) obtain preliminary evidence ability SU5416 reverse platinum resistance patient platinum-refractory ovarian carcinoma .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Must histopathologically document epithelial ovarian carcinoma confirm Laboratory Pathology , National Cancer Institute prior start study . Also eligible patient histologic diagnosis : Recurrent primary fallopian tube cancer ; Recurrent primary peritoneal cancer ( nonmesothelioma ) . Must either measurable disease physical exam radiographic imaging , patient must evaluable disease . Evaluable disease include patient thirdspace fluid accumulation proven positive adenocarcinoma ; patient elevate CA125 100 IU per mL . Must platinumrefractory disease ( persistent recurrent disease within 6 month last cisplatin carboplatin therapy ) . Must life expectancy 2 month . Must ECOG performance status 0 , 1 , 2 . No patient medical surgical complication require immediate intervention , may enroll resolution acute problem ( e.g . impend bowel obstruction , active infection , etc. ) . PT PTT must less 1.5 time upper limit normal . Must recover toxicity relate prior therapy NCI/CTEP Grade 0 , 1 , exception peripheral neuropathy , case grade 2 toxicity permissible . Granulocyte count must great equal 1,500/mm ( 3 ) . Hemoglobin must great equal 9.0 g/dL ( pretreatment transfusion allow , provide hemoglobin maintain seven day and/or active source bleeding identify treat ) . Platelet count must great equal 100,000/mm ( 3 ) . Acute care panel ( electrolyte , BUN ) urinalysis consider normal patient judgement clinic attending ( blood glucose exclude evaluation ) . No gross abnormality present . `` Normal '' define normal range test facility test take . Hepatic function : normal bilirubin ( total ) ; ALT le 2 time upper limit normal ; AST less 2 time upper limit normal . Must capable understand signing informed consent form . Must willing travel home NIH followup visit . Must great equal 18 year age . Must able willing follow instruction conform protocol . Prior chemotherapy must stop least 4 week prior enrollment . Mitomycin C nitrosoureas stop least 6 week prior enrollment . Must fail three prior chemotherapy regimen . Retreatment patient initially sensitive platinum either regimen platinum single agent would constitute one prior regimen . No history external beam radiation . Patients capable childbearing must use effective birth control study . No nonskin malignancy melanoma within past 5 year . No active infection , include positive serology HIV . Patients suppressive antibiotic therapy evaluate casebycase basis . No history brain metastasis . No uncompensated coronary artery disease electrocardiogram physical examination , history myocardial infarction severe/unstable angina past 6 month . No diabetes mellitus severe peripheral vascular disease deep venous arterial thrombosis ( include pulmonary embolism ) within 3 month entry . No New York class IIIV congestive heart failure , chronic obstructive lung disease require oxygen therapy medication , uncontrolled seizure activity . Uncomplicated asthma allow . No active therapy angina . Must undergone bone marrow transplant regimen . No pregnant breastfeeding individual . Must noncancer lifethreatening illness , include untreated infection ( must least 1 week antibiotic therapy begin cycle 1 SU5416 ) . No nonepithelial histology . No peripheral neuropathy , NCI CTEP grade 3 4 .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>DNA Damage</keyword>
	<keyword>DNA Repair</keyword>
	<keyword>FLK-1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>VEGF</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Platinum-Refractory Disease</keyword>
</DOC>